Anis Fahandej-Sadi
Anis Fahandej-Sadi is the Founder and Head Editor of TLDR Biotech (https://tldrbio.tech/), a daily newsletter delivering all the top biotech and pharma stories straight to your inbox in one daily email. Formerly working in business development within the life sciences and biotech space, Anis holds a Master of Science in Chemistry from the University of Alberta. He's passionate about the business of biotech and the next generation of regenerative medicines. You can connect with him on LinkedIn (https://www.linkedin.com/in/anisfsadi/).
Posts by: Anis
Lowering CAR T costs: Paths to more affordable cell therapies
Cancer treatment has advanced dramatically, but a central challenge remains: the newest tools in our arsenal are shockingly expensive. CAR T-cell therapies exemplify this—they’re amazing at fighting blood cancers, but a single treatment costs upwards of US$500,000.* These costs are prohibitive, even in wealthy nations, so we need strategies to drive down prices and create […]
CGT SWOT analysis offers clues on where the industry is heading
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in 2023 alone, and 2024 may see as many […]